Alliance for Clinical Trials in Oncology

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2011-01-01

Employees: 251

Market Cap: -

Website: https://www.allianceforclinicaltrialsinoncology.org

Clinical Trials

Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Other: placebo
Drug: flutamide

First Posted Date: 2004-06-22

Last Posted Date: 2016-07-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 63

Registration Number: NCT00006214

Locations: 🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸
CCOP - Wichita, Wichita, Kansas, United States
🇺🇸
CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States

and more 20 locations

Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: gemcitabine hydrochloride

First Posted Date: 2004-06-18

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 22

Registration Number: NCT00005829

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: carmustine
Drug: chemotherapy
Drug: cisplatin
Drug: etoposide
Radiation: radiation therapy

First Posted Date: 2004-06-17

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 93

Registration Number: NCT00003996

Locations: 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸
CCOP - Wichita, Wichita, Kansas, United States
🇺🇸
CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States

and more 16 locations

Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate

First Posted Date: 2004-06-16

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 34

Registration Number: NCT00003829

Locations: 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸
Quain & Ramstad Clinic, P.C., Bismarck, North Dakota, United States
🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States

and more 14 locations

Quality of Life Assessment of Patients Receiving Treatment for Esophageal Cancer [Companion to CALGB-9781]

Terminated

Conditions: Esophageal Cancer

First Posted Date: 2004-06-16

Last Posted Date: 2016-07-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 56

Registration Number: NCT00003381

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States
🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States

and more 41 locations

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase 1

Withdrawn

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Biological: alemtuzumab
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: melphalan
Drug: mycophenolate mofetil
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2004-06-11

Last Posted Date: 2019-11-27

Lead Sponsor: Alliance for Clinical Trials in Oncology

Registration Number: NCT00085449

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States

and more 21 locations

Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: methotrexate
Drug: vincristine sulfate
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-06-10

Last Posted Date: 2016-07-14

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 36

Registration Number: NCT00002676

Locations: 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸
CCOP - Kalamazoo, Kalamazoo, Michigan, United States

and more 18 locations

Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: filgrastim
Drug: paclitaxel
Drug: topotecan hydrochloride

First Posted Date: 2004-06-03

Last Posted Date: 2016-07-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 38

Registration Number: NCT00004055

Locations: 🇺🇸
CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States
🇺🇸
CCOP - Duluth, Duluth, Minnesota, United States
🇺🇸
CentraCare Clinic, Saint Cloud, Minnesota, United States

and more 16 locations

Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2004-05-26

Last Posted Date: 2016-07-14

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 51

Registration Number: NCT00005059

Locations: 🇺🇸
Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸
CCOP - Duluth, Duluth, Minnesota, United States
🇺🇸
CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States

and more 15 locations

Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: lomustine
Drug: procarbazine hydrochloride
Drug: vincristine sulfate
Radiation: low-LET photon therapy

First Posted Date: 2004-05-26

Last Posted Date: 2016-07-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 43

Registration Number: NCT00002806

Locations: 🇺🇸
CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States
🇺🇸
CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
🇺🇸
Siouxland Hematology-Oncology, Sioux City, Iowa, United States

and more 14 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy